Paradoxical inflammation induced by anti-TNF agents in patients with IBD

Nature Reviews Gastroenterology and Hepatology

Volumn 9, Issue 9, 2012, Pages 496-503

  Cleynen, Isabelle ^a   Vermeire, Séverine ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ALPHA INTERFERON; ANTIBIOTIC AGENT; ANTIFUNGAL AGENT; ANTIHISTAMINIC AGENT; ANTIVIRUS AGENT; AUTOANTIBODY; CERTOLIZUMAB PEGOL; CORTICOSTEROID; DISINFECTANT AGENT; EFALIZUMAB; ETANERCEPT; INFLIXIMAB; INTERLEUKIN 17; INTERLEUKIN 1BETA; INTERLEUKIN 21; INTERLEUKIN 22; INTERLEUKIN 6; RITUXIMAB; TUMOR NECROSIS FACTOR INHIBITOR; VITAMIN D DERIVATIVE;

ALOPECIA AREATA; ANKYLOSING SPONDYLITIS; ARTHRALGIA; ARTHRITIS; AUTOIMMUNITY; CROHN DISEASE; CUTANEOUS VASCULITIS; CYTOKINE PRODUCTION; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG ERUPTION; DRUG EXPOSURE; DRUG WITHDRAWAL; DRY SKIN; ECZEMA; ENTERITIS; GENETIC PREDISPOSITION; HUMAN; INFLAMMATION; INJECTION SITE REACTION; MORNING STIFFNESS; NONHUMAN; OUTCOME ASSESSMENT; POLYARTHRITIS; PRIORITY JOURNAL; PSORIASIFORM ECZEMA; PSORIASIS; PSORIATIC ARTHRITIS; PUSTULOSIS PALMOPLANTARIS; REVIEW; RHEUMATOID ARTHRITIS; SARCOIDOSIS; SKIN DEFECT; SKIN INFLAMMATION; SKIN MANIFESTATION; SUPERINFECTION; SYMPTOM; ULCERATIVE COLITIS; VASCULITIS;

ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ARTHRITIS; DISEASE MANAGEMENT; DRUG ERUPTIONS; HUMANS; INFLAMMATORY BOWEL DISEASES; PREVALENCE; SARCOIDOSIS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84865732639     PISSN: 17595045     EISSN: 17595053     Source Type: Journal    
DOI: 10.1038/nrgastro.2012.125     Document Type: Review

References (109)

1. Peyrin-Biroulet, L. Anti-TNF therapy in inflammatory bowel diseases: a huge review. Minerva Gastroenterol. Dietol. 56, 233-243 (2010).
2. Wiens, A., Venson, R., Correr, C. J., Otuki, M. F. & Pontarolo, R. Meta-analysis of the efficacy and safety of adalimumab, etanercept, and infliximab for the treatment of rheumatoid arthritis. Pharmacotherapy 30, 339-353 (2010).
3. Reed, M. R. & Taylor, A. L. Tumour necrosis factor inhibitors in ankylosing spondylitis. Intern. Med. J. 38, 781-789 (2008).
4. Gottlieb, A. B. et al. Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial. J. Am. Acad. Dermatol. 51, 534-542 (2004). (Pubitemid 39278071)
5. Mease, P. TNFalpha therapy in psoriatic arthritis and psoriasis. Ann. Rheum. Dis. 63, 755-758 (2004). (Pubitemid 38850443)
6. Menter, A. The status of biologic therapies in the treatment of moderate to severe psoriasis. Cutis 84, 14-24 (2009).
7. Papp, K. A. et al. A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction. Br. J. Dermatol. 152, 1304-1312 (2005). (Pubitemid 40933433)
8. Heldmann, F. et al. The European ankylosing spondylitis infliximab cohort (EASIC): a European multicentre study of long term outcomes in patients with ankylosing spondylitis treated with infliximab. Clin. Exp. Rheumatol. 29, 672-680 (2011).
9. Mease, P. J. Certolizumab pegol in the treatment of rheumatoid arthritis: a comprehensive review of its clinical efficacy and safety. Rheumatology (Oxford) 50, 261-270 (2011).
10. Ngo, B. et al. Tumor necrosis factor blockade for treatment of inflammatory bowel disease: efficacy and safety. Curr. Mol. Pharmacol. 3, 145-152 (2010).
11. Voulgari, P. V. Golimumab: a new anti-TNF-alpha agent for rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis. Expert Rev. Clin. Immunol. 6, 721-733 (2010).
12. Ramiro, S., van Tubergen, A. M. & Landewe, R. B. RAPID and FAST4WARD trials: certolizumab pegol for rheumatoid arthritis. Expert Rev. Clin. Immunol. 6, 713-720 (2010).
13. D'Haens, G. et al. Endoscopic and histological healing with infliximab anti-tumor necrosis factor antibodies in Crohn's disease: a European multicenter trial. Gastroenterology 116, 1029-1034 (1999). (Pubitemid 29203012)
14. Bongartz, T. et al. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 295, 2275-2285 (2006). (Pubitemid 43736578)
15. Fidder, H. H. et al. Long-term safety of infliximab for the treatment of inflammatory bowel disease: a single center cohort study. Gut 58, 501-508 (2009).
16. Baraliakos, X. et al. Persistent clinical efficacy and safety of infliximab in ankylosing spondylitis after 8 years-early clinical response predicts long-term outcome. Rheumatology (Oxford) 50, 1690-1699 (2011).
17. Kievit, W. et al. Long-term effectiveness and safety of TNF-blocking agents in daily clinical practice: results from the Dutch Rheumatoid Arthritis Monitoring register. Rheumatology (Oxford) 50, 196-203 (2011).
18. Komano, Y. et al. Incidence and risk factors for serious infection in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors: a report from the Registry of Japanese Rheumatoid Arthritis Patients for Longterm Safety. J. Rheumatol. 38, 1258-1264 (2011).
19. Hoentjen, F. & van Bodegraven, A. A. Safety of anti-tumor necrosis factor therapy in inflammatory bowel disease. World J. Gastroenterol. 15, 2067-2073 (2009).
20. Kircik, L. H. & Del Rosso, J. Q. Anti-TNF agents for the treatment of psoriasis. J. Drugs Dermatol. 8, 546-559 (2009).
21. Markatseli, T. E., Alamanos, Y., Saougou, I., Voulgari, P. V. & Drosos, A. A. Survival of TNF-alpha antagonists in rheumatoid arthritis: a long-term study. Clin. Exp. Rheumatol. 30, 31-38 (2012).
22. Colombel, J. F. et al. Adalimumab safety in global clinical trials of patients with Crohn's disease. Inflamm. Bowel Dis. 15, 1308-1319 (2009).
23. Adams, D. R., Buckel, T. & Sceppa, J. A. Infliximab associated new-onset psoriasis. J. Drugs Dermatol. 5, 178-179 (2006).
24. Angelucci, E., Cocco, A., Viscido, A., Vernia, P. & Caprilli, R. Another paradox in Crohn's disease: new onset of psoriasis in a patient receiving tumor necrosis factor-alpha antagonist. Inflamm. Bowel Dis. 13, 1059-1061 (2007). (Pubitemid 47309982)
25. Cohen, J. D. et al. Psoriasis induced by tumor necrosis factor-alpha antagonist therapy: a case series. J. Rheumatol. 34, 380-385 (2007).
26. Collamer, A. N., Guerrero, K. T., Henning, J. S. & Battafarano, D. F. Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: a literature review and potential mechanisms of action. Arthritis Rheum. 59, 996-1001 (2008). (Pubitemid 351990997)
27. Conklin, L. S., Cohen, B., Wilson, L., Cuffari, C. & Oliva-Hemker, M. Rash induced by anti-tumor necrosis factor agents in an adolescent with Crohn's disease. Nat. Rev. Gastroenterol. Hepatol. 7, 174-177 (2010).
28. Costa-Romero, M., Coto-Segura, P., Suarez-Saavedra, S., Ramos-Polo, E. & Santos-Juanes, J. Guttate psoriasis induced by infliximab in a child with Crohn's disease. Inflamm. Bowel Dis. 14, 1462-1463 (2008).
29. English, P. L. & Vender, R. Occurrence of plantar pustular psoriasis during treatment with infliximab. J. Cutan. Med. Surg. 13, 40-42 (2009).
30. Goldstein, J. & Levine, J. Infliximab-induced psoriaform rash. Clin. Gastroenterol. Hepatol. 8, A24 (2010).
31. Hiremath, G., Duffy, L. & Leibowitz, I. Infliximab-induced psoriasis in children with inflammatory bowel disease. J. Pediatr. Gastroenterol. Nutr. 52, 230-232 (2011).
32. Iborra, M., Beltran, B., Bastida, G., Aguas, M. & Nos, P. Infliximab and adalimumab-induced psoriasis in Crohn's disease: a paradoxical side effect. J. Crohns Colitis 5, 157-161 (2011).
33. Laga, A. C., Vleugels, R. A., Qureshi, A. A. & Velazquez, E. F. Histopathologic spectrum of psoriasiform skin reactions associated with tumor necrosis factor-alpha inhibitor therapy. A study of 16 biopsies. Am. J. Dermatopathol. 32, 568-573 (2010).
34. Manni, E. & Barachini, P. Psoriasis induced by infliximab in a patient suffering from Crohn's disease. Int. J. Immunopathol. Pharmacol. 22, 841-844 (2009).
35. Medkour, F. et al. Development of diffuse psoriasis with alopecia during treatment of Crohn's disease with infliximab. Gastroenterol. Clin. Biol. 34, 140-141 (2010).
36. Papadavid, E., Gazi, S., Dalamaga, M., Stavrianeas, N. & Ntelis, V. Palmoplantar and scalp psoriasis occurring during anti-tumour necrosis factor-alpha therapy: a case series of four patients and guidelines for management. J. Eur. Acad. Dermatol. Venereol. 22, 380-382 (2008). (Pubitemid 351247441)
37. Park, B. C. et al. Repeated paradoxical aggravation of preexisting psoriasis during infliximab treatment for Crohn's disease. Ann. Dermatol. 21, 60-62 (2009).
38. Passarini, B. et al. Cutaneous manifestations in inflammatory bowel diseases: eight cases of psoriasis induced by anti-tumor-necrosis-factor antibody therapy. Dermatology 215, 295-300 (2007). (Pubitemid 47519257)
39. Peramiquel, L. et al. Onset of flexural psoriasis during infliximab treatment for Crohn's disease. Clin. Exp. Dermatol. 30, 713-714 (2005). (Pubitemid 41499838)
40. Perez-Perez, L., Caeiro, J. L., Fabeiro, J. M., Allegue, F. & Zulaica, A. Induction of pustular lesions during infliximab therapy for Crohn's disease. Acta Derm. Venereol. 88, 292-293 (2008). (Pubitemid 351743884)
41. Pirard, D., Arco, D., Debrouckere, V. & Heenen, M. Anti-tumor necrosis factor alpha-induced psoriasiform eruptions: three further cases and current overview. Dermatology 213, 182-186 (2006). (Pubitemid 44567826)
42. Pourciau, C. & Shwayder, T. Occurrence of pustular psoriasis after treatment of Crohn disease with infliximab. Pediatr. Dermatol. 27, 539-540 (2010).
43. Takahashi, H. et al. Psoriasiform and pustular eruption induced by infliximab. J. Dermatol. 34, 468-472 (2007). (Pubitemid 46956592)
44. Umeno, J. et al. Psoriasis during anti-tumor necrosis factor-alpha therapy for Crohn's disease. Inflamm. Bowel Dis. 13, 1188-1189 (2007). (Pubitemid 47402610)
45. Verea, M. M., Del Pozo, J., Yebra-Pimentel, M. T., Porta, A. & Fonseca, E. Psoriasiform eruption induced by infliximab. Ann. Pharmacother. 38, 54-57 (2004). (Pubitemid 38018006)
46. Wollina, U. et al. Tumor necrosis factor-alpha inhibitor-induced psoriasis or psoriasiform exanthemata: first 120 cases from the literature including a series of six new patients. Am. J. Clin. Dermatol. 9, 1-14 (2008).
47. Baumgart, D. C., Grittner, U., Steingraber, A., Azzaro, M. & Philipp, S. Frequency, phenotype, outcome, and therapeutic impact of skin reactions following initiation of adalimumab therapy: experience from a consecutive cohort of inflammatory bowel disease patients. Inflamm. Bowel Dis. 17, 2512-2520 (2011).
48. Cullen, G., Kroshinsky, D., Cheifetz, A. S. & Korzenik, J. R. Psoriasis associated with anti-tumour necrosis factor therapy in inflammatory bowel disease: a new series and a review of 120 cases from the literature. Aliment. Pharmacol. Ther. 34, 1318-1327 (2011).
49. Ettler, J., Wetter, D. A. & Pittelkow, M. R. Pityriasis amiantacea: a distinctive presentation of psoriasis associated with tumour necrosis factor-alpha inhibitor therapy. Clin. Exp. Dermatol. http://dx.doi.org/10.1111/ j.1365-22302011.04286.x.
50. Klein, R. Q., Spivack, J. & Choate, K. A. Psoriatic skin lesions induced by certolizumab pegol. Arch. Dermatol. 146, 1055-1056 (2010).
51. Rahier, J. F. et al. Severe skin lesions cause patients with inflammatory bowel disease to discontinue anti-tumor necrosis factor therapy. Clin. Gastroenterol. Hepatol. 8, 1048-1055 (2010).
52. Cleynen, I. et al. Anti-TNF induced cutaneous lesions in IBD patients: characterization and search for predisposing factors. Gut 59, A1 (2010).
53. Harrison, M. J. et al. Rates of new-onset psoriasis in patients with rheumatoid arthritis receiving anti-tumour necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics Register. Ann. Rheum. Dis. 68, 209-215 (2009).
54. Dalkilic, E. et al. Tumor necrosis factor-alpha antagonist therapy-induced psoriasis in Turkey: analysis of 514 patients. Mod. Rheumatol. http://dx.doi.org/10.1007/s10165-011-0590-9.
55. de Gannes, G. C. et al. Psoriasis and pustular dermatitis triggered by TNF-{alpha} inhibitors in patients with rheumatologic conditions. Arch. Dermatol. 143, 223-231 (2007). (Pubitemid 46294587)
56. Ko, J. M., Gottlieb, A. B. & Kerbleski, J. F. Induction and exacerbation of psoriasis with TNF-blockade therapy: a review and analysis of 127 cases. J. Dermatolog. Treat. 20, 100-108 (2009).
57. Perez-Zafrilla, B., Angel Descalzo, M. & Carmona, L. Adverse reactions related to the administration of TNF inhibitors. Analysis of a registry of biologic therapy [Spanish]. Reumatol. Clin. 4, 90-95 (2008). (Pubitemid 351879629)
58. Beccastrini, E., Squatrito, D., Emmi, G., Fabbri, P. & Emmi, L. Alopecia areata universalis during off-label treatment with infliximab in a patient with Behcet disease. Dermatol. Online J. 16, 15 (2010).
59. Chaves, Y. et al. Alopecia areata universalis during treatment of rheumatoid arthritis with anti-TNF-alpha antibody (adalimumab). Dermatology 217, 380 (2008).
60. Doyle, L. A. et al. Psoriatic alopecia/alopecia areata-like reactions secondary to anti-tumor necrosis factor-alpha therapy: a novel cause of noncicatricial alopecia. Am. J. Dermatopathol. 33, 161-166 (2011).
61. Exarchou, S. A., Voulgari, P. V., Markatseli, T. E., Zioga, A. & Drosos, A. A. Immune-mediated skin lesions in patients treated with anti-tumour necrosis factor alpha inhibitors. Scand. J. Rheumatol. 38, 328-331 (2009).
62. Ferran, M., Calvet, J., Almirall, M., Pujol, R. M. & Maymo, J. Alopecia areata as another immune-mediated disease developed in patients treated with tumour necrosis factor-alpha blocker agents: report of five cases and review of the literature. J. Eur. Acad. Dermatol. Venereol. 25, 479-484 (2011).
63. Kirshen, C. & Kanigsberg, N. Alopecia areata following adalimumab. J. Cutan. Med. Surg. 13, 48-50 (2009).
64. Le Bidre, E. et al. Alopecia areata during anti-TNF alpha therapy: nine cases [French]. Ann. Dermatol. Venereol. 138, 285-293 (2011).
65. Pan, Y. & Rao, N. A. Alopecia areata during etanercept therapy. Ocul. Immunol. Inflamm. 17, 127-129 (2009).
66. Pelivani, N., Hassan, A. S., Braathen, L. R., Hunger, R. E. & Yawalkar, N. Alopecia areata universalis elicited during treatment with adalimumab. Dermatology 216, 320-323 (2008). (Pubitemid 351630097)
67. Fujikawa, K. et al. Cutaneous vasculitis induced by TNF inhibitors: a report of three cases. Mod. Rheumatol. 20, 86-89 (2010).
68. Ramos-Casals, M., Brito-Zeron, P., Cuadrado, M. J. & Khamashta, M. A. Vasculitis induced by tumor necrosis factor-targeted therapies. Curr. Rheumatol. Rep. 10, 442-448 (2008).
69. Roux, C. H., Brocq, O., Albert, C. B. V. & Euller-Ziegler, L. Cutaneous vasculitis and glomerulonephritis in a patient taking the anti-TNF alpha agent etanercept for rheumatoid arthritis. Joint Bone Spine 71, 444-445 (2004). (Pubitemid 39335685)
70. Flendrie, M. et al. Dermatological conditions during TNF-alpha-blocking therapy in patients with rheumatoid arthritis: a prospective study. Arthritis Res. Ther. 7, R666-R676 (2005).
71. Pontikaki, I. et al. Skin manifestations induced by TNF-alpha inhibitors in juvenile idiopathic arthritis. Clin. Rev. Allergy Immunol. 42, 131-134 (2012).
72. Vermeire, S. et al. Autoimmunity associated with anti-tumor necrosis factor alpha treatment in Crohn's disease: a prospective cohort study. Gastroenterology 125, 32-39 (2003). (Pubitemid 36799104)
73. Van Moerkercke, W. et al. Anti-TNFa induced severe arthralgia as a manifestation of autoimmunity? Gastroenterology 138 (Suppl. 61), S60-S61 (2010).
74. Rozenbaum, M., Boulman, N., Slobodin, G., Ayubkhanov, E. & Rosner, I. Polyarthritis flare complicating rheumatoid arthritis infliximab therapy: a paradoxic adverse reaction. J. Clin. Rheumatol. 12, 269-271 (2006). (Pubitemid 44915322)
75. Fok, K. C., Ng, W. W., Henderson, C. J. & Connor, S. J. Cutaneous sarcoidosis in a patient with ulcerative colitis on infliximab. J. Crohns Colitis http://dx.doi.org/10.1016/j.crohns.2012.01.008.
76. Gifre, L. et al. Lung sarcoidosis induced by TNF antagonists in rheumatoid arthritis: a case presentation and a literature review. Arch. Bronconeumol. 47, 208-212 (2011).
77. Shin, J. I. & Kim, D. S. Development of sarcoidosis during anti-TNF-alpha treatment: what is the mechanism? Clin. Exp. Rheumatol. 27, 1054 (2009).
78. Tong, D., Manolios, N., Howe, G. & Spencer, D. New onset sarcoid-like granulomatosis developing during anti-TNF therapy: an under-recognised complication. Int. Med. J. 42, 89-94 (2012).
79. Croft, A. P. et al. Refractory multisystem sarcoidosis responding to infliximab therapy. Clin. Rheumatol. http://dx.doi.org/10.1007/s10067-011-1933- 9.
80. Erckens, R. J., Mostard, R. L., Wijnen, P. A., Schouten, J. S. & Drent, M. Adalimumab successful in sarcoidosis patients with refractory chronic non-infectious uveitis. Graefes Arch. Clin. Exp. Ophthalmol. 250, 713-720 (2012).
81. Duerr, R. H. et al. A genome-wide association study identifies IL23R as an inflammatory bowel disease gene. Science 314, 1461-1463 (2006). (Pubitemid 44871953)
82. Garcia, V. E. et al. Detailed genetic characterization of the interleukin-23 receptor in psoriasis. Genes Immun. 9, 546-555 (2008).
83. Capon, F. et al. Sequence variants in the genes for the interleukin-23 receptor (IL23R) and its ligand (IL12B) confer protection against psoriasis. Hum. Genet. 122, 201-206 (2007). (Pubitemid 47241785)
84. Cargill, M. et al. A large-scale genetic association study confirms IL12B and leads to the identification of IL23R as psoriasis-risk genes. Am. J. Hum. Genet. 80, 273-290 (2007). (Pubitemid 46175676)
85. Nair, R. P. et al. Genome-wide scan reveals association of psoriasis with IL-23 and NF-kappaB pathways. Nat. Genet. 41, 199-204 (2009).
86. Chang, M. et al. Variants in the 5q31 cytokine gene cluster are associated with psoriasis. Genes Immun. 9, 176-181 (2008). (Pubitemid 351351659)
87. Barrett, J. C. et al. Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease. Nat. Genet. 40, 955-962 (2008).
88. Franke, A. et al. Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci. Nat. Genet. 42, 1118-1125 (2011).
89. Hugot, J. P. et al. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature 411, 599-603 (2001).
90. Liu, Y. et al. A genome-wide association study of psoriasis and psoriatic arthritis identifies new disease loci. PLoS Genet. 4, e1000041 (2008).
91. Schrodi, S. J. Genome-wide association scan in psoriasis: new insights into chronic inflammatory disease. Expert Rev. Clin. Immunol. 4, 565-571 (2008).
92. Morar, N., Cookson, W. O., Harper, J. I. & Moffatt, M. F. Filaggrin mutations in children with severe atopic dermatitis. J. Invest. Dermatol. 127, 1667-1672 (2007). (Pubitemid 46933399)
93. Palmer, C. N. et al. Common loss-of-function variants of the epidermal barrier protein filaggrin are a major predisposing factor for atopic dermatitis. Nat. Genet. 38, 441-446 (2006).
94. Duffin, K. C., Woodcock, J. & Krueger, G. G. Genetic variations associated with psoriasis and psoriatic arthritis found by genome-wide association. Dermatol. Ther. 23, 101-113 (2010).
95. Elder, J. T. Genome-wide association scan yields new insights into the immunopathogenesis of psoriasis. Genes Immun. 10, 201-209 (2009).
96. de Cid, R. et al. Deletion of the late cornified envelope LCE3B and LCE3C genes as a susceptibility factor for psoriasis. Nat. Genet. 41, 211-215 (2009).
97. Gershov, D., Kim, S., Brot, N. & Elkon, K. B. C-Reactive protein binds to apoptotic cells, protects the cells from assembly of the terminal complement components, and sustains an antiinflammatory innate immune response: implications for systemic autoimmunity. J. Exp. Med. 192, 1353-1364 (2000).
98. Casiano, C. A. & Tan, E. M. Recent developments in the understanding of antinuclear antibodies. Int. Arch. Allergy Immunol. 111, 308-313 (1996). (Pubitemid 26390329)
99. Postal, M. & Appenzeller, S. The role of tumor necrosis factor-alpha (TNF-α) in the pathogenesis of systemic lupus erythematosus. Cytokine 56, 537-543 (2011).
100. Palucka, A. K., Blanck, J. P., Bennett, L., Pascual, V. & Banchereau, J. Cross-regulation of TNF and IFN-alpha in autoimmune diseases. Proc. Natl Acad. Sci. USA 102, 3372-3377 (2005). (Pubitemid 40328052)
101. Dass, S., Vital, E. M. & Emery, P. Development of psoriasis after B cell depletion with rituximab. Arthritis Rheum. 56, 2715-2718 (2007). (Pubitemid 47237290)
102. Markatseli, T. E., Kaltsonoudis, E. S., Voulgari, P. V., Zioga, A. & Drosos, A. A. Induction of psoriatic skin lesions in a patient with rheumatoid arthritis treated with rituximab. Clin. Exp. Rheumatol. 27, 996-998 (2009).
103. Balato, A., La Bella, S., Gaudiello, F. & Balato, N. Efalizumab-induced guttate psoriasis. Successful management and re-treatment. J. Dermatolog. Treat. 19, 182-184 (2008). (Pubitemid 351883003)
104. Firmin, D., Roguedas, A. M., Lemasson, G., Abgrall, J. F. & Misery, L. Eczematous dermatosis and thrombocytosis induced by efalizumab: two new side effects. Dermatology 217, 203-206 (2008).
105. Ellinghaus, D. et al. Combined analysis of genome-wide association studies for Crohn disease and psoriasis identifies seven shared susceptibility loci. Am. J. Hum. Genet. 90, 636-647 (2012).
106. Kobayashi, T. et al. IL23 differentially regulates the Th1/Th17 balance in ulcerative colitis and Crohn's disease. Gut 57, 1682-1689 (2008).
107. Seiderer, J. et al. Role of the novel Th17 cytokine IL-17F in inflammatory bowel disease (IBD): upregulated colonic IL-17F expression in active Crohn's disease and analysis of the IL17F p.His161Arg polymorphism in IBD. Inflamm. Bowel Dis. 14, 437-445 (2008). (Pubitemid 351571823)
108. Leung, D. Y. Atopic dermatitis: new insights and opportunities for therapeutic intervention. J. Allergy Clin. Immunol. 105, 860-876 (2000). (Pubitemid 30324392)
109. Ma, H. L. et al. Tumor necrosis factor alpha blockade exacerbates murine psoriasis-like disease by enhancing Th17 function and decreasing expansion of Treg cells. Arthritis Rheum. 62, 430-440 (2010).